Promising plasmid DNA vector based on APTES-modified silica nanoparticles
Tuck-yun Cheang1,*, Bing Tang1,*, An-wu Xu2, Guang-qi Chang1, Zuo-jun Hu1, Wei-ling He1, Zhou-hao Xing2, Jian-bo Xu1, Mian Wang1, Shen-ming Wang11Department of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 2Division of Nanomaterials and Chemistry, Hefei...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bce4bde9a396456492b272c09633261b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Tuck-yun Cheang1,*, Bing Tang1,*, An-wu Xu2, Guang-qi Chang1, Zuo-jun Hu1, Wei-ling He1, Zhou-hao Xing2, Jian-bo Xu1, Mian Wang1, Shen-ming Wang11Department of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 2Division of Nanomaterials and Chemistry, Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, China  *Both authors contributed equally to this workAbstract: Nanoparticles have an enormous potential for development in biomedical applications, such as gene or drug delivery. We developed and characterized aminopropyltriethoxysilane-functionalized silicon dioxide nanoparticles (APTES-SiNPs) for gene therapy. Lipofectamine® 2000, a commonly used agent, served as a contrast. We showed that APTES-SiNPs had a gene transfection efficiency almost equal to that of Lipofectamine 2000, but with lower cytotoxicity. Thus, these novel APTES-SiNPs can achieve highly efficient transfection of plasmid DNA, and to some extent reduce cytotoxicity, which might overcome the critical drawbacks in vivo of conventional carriers, such as viral vectors, organic polymers, and liposomes, and seem to be a promising nonviral gene therapy vector.Keywords: aminopropyltriethoxysilane, silicon dioxide nanoparticles, Lipofectamine® 2000, gene therapy vector, nanomedicine |
|---|